A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer

تاریخ : ۱۳۹۳/۱۱/۱۳ / تعداد بازدید : ۲۹۳

Abstract

Background:

Erlotinib induced skin toxicity has been associated with clinical benefit in several tumour types. This phase II study evaluated the efficacy of erlotinib, dose escalated to rash, in patients with advanced pancreatic cancer previously treated with gemcitabine.

Methods:

Erlotinib was given at an initial dose of 150 mg/day, and the dose was escalated by 50 mg every 2 weeks (to a maximum of 300 mg/day) until >grade 1 rash or other dose limiting toxicities occurred. Erlotinib pharmacokinetics were performed, and baseline tumour tissue was collected for mutational analysis and epidermal growth factor receptor (EGFR) expression. The primary end-point was the disease control rate (objective response and stable disease >8 weeks).

Results:

Fifty-one patients were accrued, and 49 received treatment. Dose-escalation to 200–300 mg of erlotinib was possible in 9/49 (18%) patients. The most commonPgrade 3 adverse events included fatigue (6%), rash (4%) and diarrhoea (4%). Thirty-seven patients were evaluable for response, and the best response was stable disease in 12 patients (32% (95% confidence interval (CI) 17–47%)). Disease control was observed in nine patients (24% (95% CI: 10–38%)). Median survival was 3.8 months, and 6 month overall survival rate was 32% (95% CI 19–47%). Mutational analysis and EGFR expression were performed on 29 patients, with 93% havingKRASmutations, none havingEGFRmutations, and 86% expressing EGFR. NeitherKRASmutational status nor EGFR expression was associated with survival.

Conclusions:

Erlotinib dose escalated to rash was well tolerated but not associated with significant efficacy in non-selected patients with advanced pancreatic cancer.

Read full article: A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer

آخرین مقالات

ثبت مشخصات

نام

پست الکترونیک

کپچا

دیدگاه

A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer

Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis

دانستنی های مفید در خصوص حساسیت دارویی

دلایل و درمان سرگیجه

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosi

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis